AU2003215543A1 - Water- soluble derivatives of lipophilic drugs - Google Patents

Water- soluble derivatives of lipophilic drugs

Info

Publication number
AU2003215543A1
AU2003215543A1 AU2003215543A AU2003215543A AU2003215543A1 AU 2003215543 A1 AU2003215543 A1 AU 2003215543A1 AU 2003215543 A AU2003215543 A AU 2003215543A AU 2003215543 A AU2003215543 A AU 2003215543A AU 2003215543 A1 AU2003215543 A1 AU 2003215543A1
Authority
AU
Australia
Prior art keywords
water
soluble derivatives
lipophilic drugs
lipophilic
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215543A
Other languages
English (en)
Inventor
Min Li
Jane S. C. Tsai
Robert S. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of AU2003215543A1 publication Critical patent/AU2003215543A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9473—Anticonvulsants, e.g. phenobarbitol, phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
AU2003215543A 2002-01-25 2003-01-23 Water- soluble derivatives of lipophilic drugs Abandoned AU2003215543A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/057,762 US7029918B2 (en) 2002-01-25 2002-01-25 Water-soluble derivatives of lipophilic drugs
US10/057,762 2002-01-25
PCT/EP2003/000655 WO2003062819A2 (en) 2002-01-25 2003-01-23 Water- soluble derivatives of lipophilic drugs

Publications (1)

Publication Number Publication Date
AU2003215543A1 true AU2003215543A1 (en) 2003-09-02

Family

ID=27609480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215543A Abandoned AU2003215543A1 (en) 2002-01-25 2003-01-23 Water- soluble derivatives of lipophilic drugs

Country Status (6)

Country Link
US (2) US7029918B2 (enExample)
EP (1) EP1468295A2 (enExample)
JP (1) JP3828891B2 (enExample)
AU (1) AU2003215543A1 (enExample)
CA (1) CA2473498A1 (enExample)
WO (1) WO2003062819A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059547A2 (en) * 2003-12-12 2005-06-30 Inverness Medical Switzerland Gmbh Assay
WO2006088894A2 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH568996A5 (enExample) 1968-05-07 1975-11-14 Hoffmann La Roche
US3819602A (en) * 1968-05-07 1974-06-25 Hoffmann La Roche 7-chloro-5-(2-fluorophenyl)-1-(2-hydroxyethyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one and esters thereof
US3567710A (en) 1968-06-03 1971-03-02 Hoffmann La Roche Process for the preparation of 1,3-dihydro-2h-1,4-benzodiazepin-2-ones
US4046636A (en) 1974-06-20 1977-09-06 Syva Company Diazepam enzyme conjugates
US4043989A (en) 1975-09-11 1977-08-23 Syva Company Oxazepam derivatives for immunoassay reagents
US4083948A (en) 1977-04-04 1978-04-11 Hoffmann-La Roche, Inc. Benzodiazepine radioimmunoassay using I125-label
US4243654A (en) 1978-09-11 1981-01-06 Syva Company Oxazepam derivatives for immunoassay reagents
US4717582A (en) 1986-05-22 1988-01-05 The Dow Chemical Company Method and apparatus for controlling the density of a foam
ATE132974T1 (de) * 1986-10-24 1996-01-15 Abbott Lab Test, indikatoren, immunogene und antikörper für benzodiazepine
US5219747A (en) * 1987-01-27 1993-06-15 Hoffmann-La Roche Inc. Immunoassay for tetrahydrocannabinol metabolites
US5144030A (en) 1987-02-17 1992-09-01 Abbott Laboratories Fluorescene polarization immunoassay for tetrahydrocannabinoids
US4777169A (en) 1987-07-24 1988-10-11 Hoffmann-La Roche Inc. Benzodiazepine derivatives
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5237057A (en) 1992-04-06 1993-08-17 Biosite Diagnostics, Inc. Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
CA2167362A1 (en) 1995-02-10 1996-08-11 Alexei Dmitri Klimov Apparatus and method for conducting a binding assay on an absorbent carrier material
EP1066523A2 (en) 1998-03-27 2001-01-10 Microgenics Corporation Confirmatory assays for small molecule drugs
US5847128A (en) 1998-05-29 1998-12-08 Virginia Commonwealth University Water soluble derivatives of cannabinoids
KR20030008153A (ko) 2000-06-22 2003-01-24 파모스 코포레이션 신규 비-향정신성 카나비노이드

Also Published As

Publication number Publication date
CA2473498A1 (en) 2003-07-31
US20060024832A1 (en) 2006-02-02
EP1468295A2 (en) 2004-10-20
JP3828891B2 (ja) 2006-10-04
WO2003062819A3 (en) 2004-04-01
WO2003062819A2 (en) 2003-07-31
US20030153096A1 (en) 2003-08-14
JP2005515476A (ja) 2005-05-26
US7029918B2 (en) 2006-04-18

Similar Documents

Publication Publication Date Title
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
AU2003901813A0 (en) Pharmaceutical derivatives
AU2003273865A1 (en) Amino-propanol derivatives
IL163642A0 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2002351764A1 (en) Flavonoid compounds and their pharmaceutical uses
AU2003221699A1 (en) Pharmaceutical preparation for taste masking
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
AU2003276572A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
AU2002950657A0 (en) Derivatives of monosaccharides for drug discovery
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
AU2002346457A1 (en) Pharmaceutical formulations comprising indolinone derivatives
AU2002333276A1 (en) Drugs for vasculopaties
AU2003215543A1 (en) Water- soluble derivatives of lipophilic drugs
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2002308105A1 (en) Benzoaxathiepin derivatives and their use as medicines
AU2003242538A1 (en) Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2001292001A1 (en) Pharmaceutical oxan preparation
AU2003211267A1 (en) Solid preparations with improved absorbability of hardly water-soluble drug
AU2001276556A1 (en) Novel pharmaceutical use of quinnoline derivatives
AU2004210246B2 (en) Combination of antidiabetic drugs
AU2002319135A1 (en) Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug
AUPS208402A0 (en) Pharmaceutical derivatives
AU2003242321A1 (en) Inhibitor of anticancer drug side effect
AU2003238900A1 (en) Pharmaceutical formulation
AU2002346284A1 (en) Pharmaceutical compositions of phospholipid derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase